A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC

This study is for patients with advanced/metastatic non-small cells lung cancer (NSCLC) who have not received any treatment through the vein for the advanced disease.

Trial Details

NCT ID
NCT06246110
Phase
PHASE2
Sponsor
Eikon Therapeutics
Status
RECRUITING
Cancer Type
Non-Small Cell (NSCLC) Lung Cancer
Interventions
  • EIK1001
  • Pembrolizumab
  • Paclitaxel
  • Pemetrexed
  • Carboplatin
Locations (sample)
  • Daphne, Alabama, United States|30.60353,-87.9036
  • Chandler, Arizona, United States|33.30616,-111.84125
  • Fresno, California, United States|36.74773,-119.77237
  • Los Angeles, California, United States|34.05223,-118.24368
  • Los Angeles, California, United States|34.05223,-118.24368

Key Eligibility Criteria

  • be ≥ 18 years of age on the day of signing of informed consent.
  • confirmed Stage 4 NSCLC (squamous or non-squamous) and be considered for standard of care.
  • have confirmation that mutation-directed therapy is not indicated (documentation of absence of tumor activating mutations/fusions that are approved…
  • have at least 1 lesion with measurable disease at Baseline according to RECIST 1.1 as determined by the local site Investigator/radiology assessment.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Small Cell (NSCLC) Lung Cancer Trials on Trialify →